Business
KRTL Biotech Spotlights Anti-Infectives and Antibiotics Portfolio to Support Public Health and Global Treatment Access
KRTL Biotech Spotlights Anti-Infectives and Antibiotics Portfolio to Support Public Health and Global Treatment Access.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"\r\n\r\n \r\n \r\n KRTL Biotech Spotlights Anti-Infectives and Antibiotics Portfolio to Support Public Health and Global Treatment Access\r\n \r\n \r\n\r\n\r\nKRTL Biotech Spotlights Anti-Infectives and Antibiotics Portfolio to Support Public Health and Global Treatment Access\r\n\r\n\r\n\r\n\r\n\r\nLakewood, CO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) (\"KRTL Holding\" or the \"Company\") today announced that its majority-owned subsidiary, KRTL Biotech, Inc., is highlighting its expanded portfolio of anti-infective and antibiotic products, developed in collaboration with SIGMA Corp., as part of the Company’s broader initiative to strengthen access to essential medicines in underserved and emerging healthcare markets. The anti-infectives product line currently includes targeted, essential formulations such as: \r\n Hostess Suspension (Trimethoprim + Sulfamethoxazole) – Broad-spectrum bactericidal\r\n Positrin (Erythromycin Ethylsuccinate) – Macrolide antibiotic\r\n Taxonid (Nitazoxanide) – Broad-spectrum antiparasitic\r\n While the current portfolio is focused, SIGMA’s GMP-certified facility enables the production of a broader range of anti-infective therapies, including: \r\n Penicillin derivatives (e.g., amoxicillin)\r\n Macrolides and fluoroquinolones (e.g., azithromycin\r\n Oral suspensions and pediatric antibiotics\r\n Injectables for inpatient and outpatient treatment\r\n These existing and potential offerings are aligned with the World Health Organization’s (WHO) Model List of Essential Medicines, reinforcing KRTL Biotech’s strategy to meet critical public health needs in both regional and global markets. According to recent industry research, the global anti-infectives market—including antibiotics, antiparasitics, and related formulations—is estimated to exceed $150 billion annually. Much of this demand is driven by institutional purchasing, national health programs, and urgent care infrastructure in both developed and emerging economies. With vertically integrated operations in South America and streamlined logistics through its SIGMA facility in Cochabamba, KRTL Biotech is strategically positioned to compete on both cost and quality. The Company's scalable operations—certified under internationally recognized Good Manufa...